1 July 2026
DLA Piper advises Kartos Therapeutics in acquisition by Ipsen for up to US$1.75 billion
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Emilio Ragosa Lead | DLA Piper | Partner | Life Sciences and Healthcare | Not stated |
| Michael Patrone Lead | DLA Piper | Partner | Not stated | Not stated |
| Keith Ranta | DLA Piper | Not stated | Employee Benefits & Executive Compensation | Not stated |
| Paolo Morante | DLA Piper | Not stated | Antitrust & Competition | Not stated |
| Christopher Mikson | DLA Piper | Not stated | FDA | Not stated |
| Jonathan Elefant | DLA Piper | Not stated | Labor and Employment | Not stated |
| James McGraw | DLA Piper | Not stated | Life Sciences Licensing | Not stated |
| Arthur Cohn | DLA Piper | Not stated | Life Sciences Licensing | Not stated |
| Jeffrey Scott | DLA Piper | Not stated | Healthcare Compliance | Not stated |
| Stephan Harris | DLA Piper | Not stated | Tax | Not stated |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.75bn (US$1.75 billion)
- What the figure measures
- Total transaction value
- Client
- Kartos TherapeuticsSell-side
- Counterparties
- Ipsen (Buy-side)